Abstract: Quantification of the anticholinergic exposure insufficiently or imprecisely incorporates dosage information, leading to inaccurate estimations. The aim was to construct a novel scale, including potency and dosage for the quantification of the anticholinergic exposure in older adults. Potency information was retrieved from a previous systematic review. The dosage range for each drug was delineated in minimal, maintenance and maximal dosage for adults and older adults. Dosage information was collected from authoritative sources and reviewed in an expert panel. The Muscarinic Acetylcholinergic Receptor ANTagonist Exposure (MARANTE) scale was tested for clinimetric properties using cohorts of community-dwelling older adults and nursing home residents. After three data collection rounds, data for the dosage ranges remained incomplete for 32 active substances. Remaining gaps were filled in, and 11 dosage adjustments were proposed during the expert panel meeting. We chose the values {0; 1; 2) for the categories of potency and {0; 0.5; 1; 1.5; 2) for the levels of dosage ranges, showing good clinimetric properties. Forty-one anticholinergic drugs were prescribed in the two cohorts. Most (61%) were low potency anticholinergics and used for depression (19%, e.g. citalopram). There were 31.8% (median MARANTE 1.5, IQR 1.5-2.5) and 37.6% (median 2, IQR 1.5-2.5) anticholinergic users in the community-dwelling cohort and nursing home cohort, respectively. The MARANTE scale combines potency with the dosage spectrum, to quantify the anticholinergic exposure in older adults. An open feedback system on the list of anticholinergic and proposed anticholinergic potency and dosage values is advised.
Anticholinergics are a group of drugs that competitively inhibit the muscarinic or nicotinergic receptors both in the central nervous system (CNS) and in peripheral tissues, resulting in an inhibition of the acetylcholine (Ach) pathways [1] [2] [3] [4] [5] [6] . Apart from the pure anticholinergics, active substances with anticholinergic properties are used in a variety of diseases and symptoms including depression, psychosis, Parkinson's disease, allergy, pain and urinary incontinence. [2, 3, 7] . Some anticholinergic drugs are used therapeutically for their anticholinergic properties, while others have other primary mechanisms of action for their intended therapeutic goal, and only additionally anticholinergic properties. Therefore, these drugs and their adverse effects are not always recognized as anticholinergic [2] . Depending on the receptors affected, several adverse effects are possible. Common muscarinic central adverse events include dizziness, nervousness, delirium and hallucination [2, 4, [7] [8] [9] while the peripheral adverse events include dry mouth, constipation, blurred vision and urinary retention. Impact on nicotinic receptors might be responsible for long-term negative effect on cognition [10, 11] .
Older adults (65 years or older) consume anticholinergics more than younger patients despite the fact that they are more sensitive to the effects of these drugs [2, 4, 9] . Age-related changes in pharmacokinetics lead to a changed permeability of the blood-brain barrier, and a decreased clearance, resulting in a higher serum and brain concentration [9, [12] [13] [14] . Moreover, changes in pharmacodynamics may further augment the risk of adverse events, as the cholinergic activity is reduced because of a decrease in the number and binding affinity of receptors, homeostatic mechanisms tend to fail, and signal transduction is diminished [15] [16] [17] [18] [19] [20] [21] . Additionally, older adults often have multimorbidity [9, [12] [13] [14] , resulting in concurrent use of multiple drugs (i.e. polypharmacy) [4, 8, 9, 14] , of which a number might produce anticholinergic effects.
Turheim stated that designing a general formula for dose adjustment in older adults is almost impossible [15] [16] [17] , because of the additional complexity of interpersonal variation, and increasing prevalence of renal and hepatic failure. Nevertheless, a number of tools have been developed to assess the intensity of the exposure to anticholinergic drugs, and to estimate and manage the risk of anticholinergic adverse events in older adults. On the one hand, one of these tools is the determination of serum anticholinergic activity (SAA), in serum samples of individual patients [2, 4] . However, this is a time-consuming, invasive, expensive method, making it a less ideal method for clinical applications [2, 4] . On the other hand, Anticholinergic Risk Scales (ARS) identify anticholinergics and quantify the exposure by categorizing them on Author for correspondence: Maarten Wauters, De Pintelaan 185, 1 blok B, 9000 Gent, Belgium (e-mail maarten.wauters@ugent.be). Shared first authorship: Therese Klamer and Maarten Wauters.
potency [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Evidence suggests that higher potency scores can lead to an impaired cognitive and physical functioning [13, 24, 32] and an increased risk of falling, leading to increased hospitalization or mortality rates [33] [34] [35] . A limitation to these ARS is the variation in the number of included drugs (sometimes because of differences in availability of anticholinergics in the countries where the scales were developed) and the accuracy of determination of anticholinergic properties. Moreover, the daily dosage is generally not taken into account [22] . The anticholinergic exposure cannot be thoroughly evaluated without precise dosage information [36] .
In an attempt to simplify and standardize the evaluation of intrinsic potency, and to avoid inconsistencies in assigning drugs with anticholinergic properties, two systematic reviews were recently published [22, 31] . These reviews combine active substances with anticholinergic activity in an international standardized list, based on the integration of the results of previous developed ARSs. However, Salahudeen et al. [31] list all anticholinergics from the ARSs, without transparent enumeration on the level of evidence of the anticholinergic properties. Both reviews categorized the intrinsic potency of each anticholinergic on the list into categories (Salahudeen in a 4-point scale, and Dur an in a 3-point scale). The authors of both systematic reviews both refrained explicitly from addressing the issue of dosage in their publications.
Until now, there is no method that combines both potency and the whole spectrum of dosage information of anticholinergic drugs, adapted for use in older adults (65 years and older). This study therefore aimed (i) to delineate the daily dosage spectrum by setting four dosage ranges (low, moderate, high and very high) for active substances with anticholinergic properties identified in Dur an's list; (ii) to create a novel scale, the Muscarinic Acetylcholinergic Receptor ANTagonist Exposure scale (MARANTE), by choosing cut-off values for the dosage ranges of each anticholinergic drug; and (iii) to construct and test clinimetric properties [37] and the distribution of scores on the MARANTE scale in two cohorts of older patients in Belgium (one cohort of community-dwelling oldest old (aged 80 years or more) [38] and one cohort of nursing home residents [39] ).
Methods
Delineating the dosage spectrum of anticholinergics. The MARANTE scale is based on the anticholinergic potency of drugs and on the daily dosage patients take of a drug. The daily dosage is the summation of all doses during the interval of a day, and a dose is the amount taken at one administration moment (expressed in mg). To organize our search for information for dosage instructions, we determined dosage concepts for younger adults (18-65 years) and for older adults (65 years and older). For means of this study, only the dosage concepts of older adults (indicated with the term 'geriatric') will be given in the results section, but we will give a comparison on the availability of data between younger and older adults.
• The (Geriatric) Minimal Effective Dose: (G)MinEV • The (Geriatric) Maintenance Dose: (G)MainD • The (Geriatric) Maximal Effective Dose: (G)MaxEV When collecting dosage information, it was expected to find multiple values for the same concept. For the (G)MinEV and (G)MainD, when sources contradict each other, a range was used (indicated by a lower and upper limit, or the lowest and highest value found for that concept, respectively), or either a pinpoint value. For the (G)MaxEV, a pinpoint value was given, as little variation was expected.
The values of the three dose concepts determined four dose ranges: low, moderate, high and very high. For use in the calculation of the MARANTE scale, the lowest dose (e.g. the lower limit in the range mentioned) was used to indicate the cut-offs. The dosage concepts, and the dosage ranges are graphically presented in Fig. 1 .
• Low: Higher than zero (0 mg) and less than the (G)MinEV;
• Moderate: Equal or higher than the (G)MinEV, but lower than the (G)MainD We limited our ambition to find dosage ranges for the subset of all active substances with anticholinergic properties, defined in the systematic review of Dur an et al. [40] , and all anticholinergics that were observed in the medication lists of two Belgian cohorts of older adults. All information was collected for use of the daily dosage (meaning irrespective of the number of administration moments in 1 day).
Collecting dosage information on dosage instructions. To define dosage ranges for all selected active substances, information on the dosage concepts was collected in three rounds from authoritative sources. All steps of data gathering were collected and documented in a transparent way.
In a first round, we collected dosage information for the main indication only from international reference sources. To determine the main indication, we consulted the World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology (http:// www.whocc.no/atc_ddd_index/). As international reference sources, we used the Drug Bank (www.drugbank.ca), Micromedex (http:// www.micromedexsolutions.com/), the Dutch website of Farmacotherapeutisch Kompas (FK; http://www.farmacotherapeutischkompas.nl/), the Belgian drug reference book BCFI (http:// www.bcfi.be/) and the British handbook Martindale (reference to book or website).
In case the information in these reference sources was insufficient or inconsistent, in the second round we retrieved new information from the European Public Assessment Report (EPAR) [28] and the Summary of Product Characteristics (SmPC) (http://www.ema.europa. eu/ema/).
When neither of these documents contained decisive information, we consulted in a third round the Geriatric Formulary from the Dutch Expertise Centre of Pharmacotherapy in Old Persons, Utrecht University (NL) (http://www.ephor.nl/eng) [42] .
We organized an expert panel to discuss the remaining missing information and discrepancies. Six experts (a neurologist, a psychiatrist, an old-age psychiatrist, a geriatrician/clinical pharmacologist and two general practitioners/clinical pharmacologists) were invited based on their expertise and experience on drug use in older patients. Prior to this expert panel, the experts had to fill in all remaining gaps in dosage values based on their experience. During the expert panel, the experts cleared any discrepancies (overlapping dosage ranges or nonspecific recommendations for dosage adjustments) through consensus. Finally, the experts also critically reviewed and controlled the remaining dosages of the remaining active substances in older adults for which data were available in the literature, to ensure uniformity. If no concrete dosage adjustment could be proposed for older adults, it was decided to take half of the dosage of younger adults. In the light of changed pharmacokinetics and pharmacodynamics in the body of an older person (e.g. a decreased renal function), or from their own clinical experience, experts could propose additional dosage adjustments which were discussed in the panel.
Creating the MARANTE scale. The MARANTE scale is intended to provide a clinical estimate of the exposure of an individual patient to anticholinergics. In later stages, it is intended to be used in the automated analysis of medication lists of older adults to create alerts for the drug prescribers.
Prerequisites are the correct identification of anticholinergics, the correct classification of their potency, as proposed by Dur an et al. [22, 40] , and the observation of the daily dosage, to determine its place in the four dosage ranges, as described above and illustrated in Fig. 1 . For each anticholinergic drug identified on a medication list, an anticholinergic load will be calculated by multiplying the potency value with the dosage range value.
The anticholinergic loads of all the anticholinergics on the medication list (with n indicating the number of drugs) are then summarized to a score on the MARANTE scale, reflecting the intensity of exposure to all anticholinergics on the drug list, and thus deemed to be indicative of the risk of anticholinergic adverse events.
The two categories of potency, as proposed by Dur an et al. [22, 40] , are low and high potency. We empirically checked the value sets of {1,2} and {1,3}. To quantify the dosage ranges (low to very high), we empirically checked approaches {0.5, 1, 1.5, 2}, {1, 2, 3, 4} and {1, 2, 4, 8}.
Exploring the clinimetric properties of the MARANTE scale. We explored the prevalence of anticholinergic drugs, and the distribution of the MARANTE scale in two cohorts of older patients in Belgium, either community-dwelling (Belfrail-Med cohort) or nursing home residents (Ageing@NH cohort). The cohorts were selected because of availability of data, and the expected high prevalence of anticholinergic users.
The mean age of the Belfrail-Med cohort was 84.4 years [38] . Furthermore, the majority of the population was female (61.2%) and used more than five drugs daily (57.7%). The study protocol for the BELF-RAIL cohort was approved by the Biomedical Ethics Committee of the Medical School of the Universit e Catholique de Louvain (UCL), Brussels (B40320084685, on 27/10/2008) and later by the Ethics committee of Ghent University Hospital (B670201421408, on 26/06/ 2014). The secondary use of the data set of this protocol was covered by this approval.
The second cohort used was a cohort of nursing home residents, derived from the Ageing at a Nursing Home (Ageing@NH) cohort, a longitudinal study of newly admitted nursing home residents. The selection of residents was made between September and December 2013, and the cohort was followed for 2 years. At baseline, their mean age was 84.2 years and 65.4% were females. For means of this study, the medication data of the surviving residents during the second follow-up year were used (n = 755). The study protocol for the Ageing@NH cohort was approved by the ethics committee of the Antwerp University Hospital Belgium (EC-number 13/43/420) [39] .
Clinimetric evaluation. We studied the clinimetric properties of the MARANTE scale by examining the histograms and skewness of the distribution of scores on the MARANTE scale (using The Kolmogorov-Smirnov test (K-S)). We examined different value sets for potency and dosage ranges for potency either {1,2} and {1,3}. For dosage ranges either {0.5, 1, 1.5, 2}, {1, 2, 3, 4} and {1, 2, 4, 8}. Selection was based on the analysis of the histograms of scoring results in two large cohorts (see earlier). Value sets leading to distributions, with empty values, overly broad or multi-modal distributions were not selected.
All statistics were performed with SPSS (IBM SPSS Statistics 22).
Results

Description of the selected anticholinergics.
Of the 100 active substances of the systematic review of Dur an et al. [22, 40] , 71 were available on the medication markets in Belgium (n = 63) and the Netherlands (n = 64). Of the 71 active substances available in Belgium and the Netherlands, 41 were actively prescribed in the two cohorts used. Some of these active substances were available in different routes of administration (e.g. aerosol therapy or nebulation in ipratropium), or in combination with other active substances (e.g. fixed-dose combinations including codeine), or as a purified enantiomer of an active substance in Dur an's list (e.g. citalopram and the S-enantiomer escitalopram). Of the 41 substances, 25 (61%) were classified as low potency and 16 (39%) were high potency anticholinergics. The main indications for which these formulations with anticholinergic properties were used included depression (18.8%, predominantly citalopram, escitalopram, amitriptyline, nortriptyline), pain (17.4%, predominantly fentanyl, tramadol, morphine) and obstructive airway diseases (15.9%, predominantly ipratropium and theophylline).
Results from the dosage information collection. After the first round of the dosage information collection, only three active substances out of Dur an's list could be matched with all dosage reference points. For the others, precise values for these concepts were not available, and recommendations for dosage adjustments in older adults were absent or unspecific.
After the second and third round, six more active substances had all dosage reference points filled in. This means that the remaining 32 active substances had incomplete data for one or more dosage ranges. For the adults concepts, we missed values for 17% of the concepts, and for older adults, we missed 55%. These gaps were then discussed in the expert panel.
After the expert panel, all drugs were matched with all dosage reference values. Also, all overlaps in dosages were clarified. Only for citalopram, there was overlap between the ranges of the minimal effective dose and the maintenance dose. These ranges were concatenated and given the value of 'low'. Other adaptations were proposed in the dosage ranges for older adults for drugs cleared by the kidney (e.g. cimetidine, tolterodine), where the dose ranges were lowered beyond the doses retrieved from the authoritative sources. For 11 drugs (e.g. triazolam, levomepromazine), the dosages of the geriatric minimal effective value were lowered, because the experts felt that the dosages retrieved from authoritative sources were still too high, based on their clinical experience with older adults.
The experts indicated that their decisions were made for use in the context of common clinical practice, but not of palliative care, as the focus of care is different. For this reason, they made suggestions for oxycodone to lower the dosages. For fentanyl, they suggested to only include the parenteral forms into the scoring for the anticholinergic exposure, as the intramuscular injection or intravenous solution is more used in anaesthesia or palliative care. The changes made by the experts are listed in Appendix 1.
The basic data for defining the dosage ranges for each of the identified anticholinergic drugs are given in Table 1 .
Clinimetric properties analysis.
Histograms were used to demonstrate the clinimetric properties of several approximations for the calculations of the MARANTE scale, examining different values for both potency (either {1,2} and {1,3}), and dosage ranges (either {0.5, 1, 1.5, 2}, {1,2, 3, 4}, or {1, 2, 4, 8}). All models resulted in a positively skewed distribution of the scores on the MAR-ANTE scale in both cohorts (with Kolmogorov-Smirnov test at the p < 0.001 level, except for the combination of the {1,2} and {1,2, 3, 4} value set).
The potency value set {1,3} was disregarded, as this approach yielded empty cells, and a multi-modal histogram.
The dosage value set {1, 2, 4, 8} created a multi-modal histogram as well, with a broad dispersion of scores in both cohorts. In addition, it overemphasizes the weight of the dosage versus potency. Therefore, this value set was disregarded.
Finally, we selected the {0.5, 1, 1.5, 2} over the {1,2, 3, 4} dosage value set, as we wanted to treat the potency and the dosage value equipotent. So, for the calculation of the scores on the MARANTE scale, we decided to use the {1,2} value set for potency and the {0.5, 1, 1.5, 2} value set for dosage.
In the Belfrail-Med cohort, we observed a prevalence of 31.8% users of anticholinergics with a median score of 1.5 (IQR 1.5-2.5, range 0-7). In the Ageing@NH cohort, the prevalence of anticholinergic users was higher: 63.5% users of anticholinergics with a median score of 2 (IQR 1.5-3.5, range 0-10.5), probably due to a higher intake of drugs and more specifically of psychotropic drugs. The final histograms for both cohorts are presented in Fig. 2 and 3 . (continued)
Discussion
Main findings.
In the present study, we developed a score to quantify the anticholinergic exposure in individual patients. This MAR-ANTE scale is designed for older adults (aged 65 years and over) and combines both potency and the full spectrum of dosage ranges of anticholinergic drugs. It provides an instrument for large-scale surveillance of the risk of exposure to the class of anticholinergics, which are widely used by older adults and are known to cause a high risk of adverse events [7, 43] . The search for detailed dosage information proved to be a laborious task, with only limited information available on dose adaptations in older adults. The sources were often non-specific, inconclusive and without specific recommendations for dosage adjustments in the older adults.
Strengths and limitations.
Strengths of the MARANTE scale are the introduction of four dosage ranges, based on three cut-off points, which lowers the chance of over-or underestimation of the true anticholinergic exposure. Furthermore, dosage information for almost half of the currently used anticholinergic drugs was completed.
We only completed the dosage information for a pragmatic sample of 41 active substances (of the 100 anticholinergics, currently used internationally) which might be seen as a limitation. However, this work needs to be completed for all the 100 anticholinergic drugs identified on the list of Dur an et al. [22] and for any newly developed active substance with anticholinergic properties. In this endeavour, we strive to collect dosage values for all remaining active substances in the following year. Next, we would like to invite the scientific community with an interest in anticholinergics, to review our findings in order to fine-tune the MARANTE scale. For this, we have created an online collaboration platform (found at: https://secureramit.ugent.be/marante/).
The starting point of this article was the systematic review of Anticholinergic Risk Scales, performed by Dur an et al. [22] . The Dur an's list may not have included active substances with anticholinergic properties, currently prescribed in significant numbers in some countries [44] or active substances recently brought onto the market. Therefore, it is advisable that the list will be reviewed with regard to systemic anticholinergic effects and usage/registration throughout the world. In addition, one may critique the simplified classification into low and high potency.
Variable interindividual effect of anticholinergics might be another difficulty [15] [16] [17] . This is not taken into account as the MARANTE scale is designed for application in larger samples. Review at patient level must be performed with caution, as individual variability in both pharmacokinetics and pharmacodynamics is quite possible. The MARANTE scale is an approximation of the degree of exposure to anticholinergic drugs, and not an approximation of the patient's body to the drugs.
Lastly, although the expert panel cleared out many inconsistencies and gaps, further evidence is needed for the confirmation of the dosage ranges of the reviewed drugs.
Comparison with other studies. Only Carnahan et al. [23] and the Drug Burden Index [13] incorporated the dosage of drugs into the quantification of the anticholinergic burden. Yet, Carnahan et al. [23] uses only the maximal effective dosage as a reference point, possibly underestimating the true anticholinergic burden. In contrast, the Drug Burden Index standardizes the actual daily dose of each drug for this minimally effective value [13] , potentially overestimating the true anticholinergic burden.
Additionally, the Drug Burden Index also includes drugs with dubious anticholinergic properties, treats all drugs as equipotent, and uses dosage reference points that were set for dosages in young adults [2] .
Implications for further research. In a next step, the clinical implications of the MARANTE scale need to be investigated. Anticholinergics have been considered as potentially inappropriate [45, 46] and are widely regarded as to be used with caution in older persons. The relationship of anticholinergic exposure (either solely based on the potency of medications, or in combination with one dosage reference point), remains inconclusive, given different designs and Anticholinergic Risk Scales used [34, [47] [48] [49] [50] . We will investigate the clinical relevance of the MARANTE scale, by searching for associations with mortality and hospitalization in the Belfrail-Med cohort.
Clinical studies are needed to test the association between the MARANTE scale as a measure of anticholinergic exposure, and the observed intensity of anticholinergic burden that might affect the quality of life in older patients. In explorative observational studies of the association between anticholinergic exposure and hard outcomes (e.g. hospitalization, mortality), the impact of the added precision and power of the MARANTE scale can be explored [51] . Additionally, it is important to replicate this present study and all above-suggested studies in a population of younger adults.
Implications for practice. By combining both potency and dosage information to calculate exposure, an extra dimension was created. This novel MARANTE scale can aid practicing physicians in prescribing and reviewing patient's drug lists, by implementation in medical software. The overview of all dosage adjustments in older patients can serve as a reference documents for prescribing in older adults. Also, prescribers can have better judgements of a patient's exposure for possible anticholinergic exposure to evaluate the patient's response to anticholinergics.
To help prescribers, drug reference book committees, regulatory agencies, as well as the pharmaceutical industry should actively exchange knowledge on dose adjustments for older adults to assure safer prescribing.
Automated tools, based on the MARANTE scale, could facilitate early recognition and monitoring of anticholinergic burden, and make more feasible the application of explicit criteria of inappropriate prescribing, as mentioned in STOPP-START, the Beers List, the EU(7)-PIM list [45, 46, 52] .
International cooperation is needed to constantly evaluate, adapt and update the basic information behind a tool, such as the MARANTE scale. Transparent management of modifications through interactive Web-based involvement of the global scientific community, could guarantee both editorial independence and state-of-the-art quality of information. Implementation in point-of-care evidence-based information systems is crucial.
